# OnCo record soho-01 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/soho-01/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "soho-01", "NCT05099172" ;
  schema:name "SOHO-01"@en ;
  schema:description "SOHO-01 is the study behind the second oral HER2 pill for lung cancer, approved in November 2025."@en ;
  schema:url <https://onco.cc/trials/soho-01/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05099172>, <https://www.bayer.com/en/us/news-stories/hyrnuo> ;
  onco:status "positive" ;
  onco:phase "1/2" ;
  schema:startDate "2021-10-25" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/her2-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/sevabertinib/> ;
  onco:companies <https://onco.cc/companies/bayer/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-soho-01-n-engl-j-med-2025/> .